InChI key
DLTOEESOSYKJBK-UHFFFAOYSA-N
InChI
1S/C23H29N3O.2ClH/c27-19-18-25-16-14-24(15-17-25)12-5-13-26-22-8-3-1-6-20(22)10-11-21-7-2-4-9-23(21)26;;/h1-4,6-11,27H,5,12-19H2;2*1H
SMILES string
Cl[H].Cl[H].OCCN1CCN(CCCN2c3ccccc3C=Cc4ccccc24)CC1
assay
≥98% (HPLC)
form
solid
storage condition
desiccated
color
yellow
solubility
H2O: ~24 mg/mL
Quality Level
General description
Opipramol acts as an antidepressant and is chemically similar to tricyclic antidepressants. It is an atypical anxiolytic and antidepressant drug. Opipramol mainly acts on sigma receptors. It is usually found to be much effective in depressive disorder. It has the ability to prevent histamine, serotonin, dopamine and alpha-1 adrenergic receptors.
Biochem/physiol Actions
σ1/σ2 opioid receptor agonist; an antagonist at D2, 5HT2 and H1 receptors; atypical antidepressant, antipsychotic and anxiolytic
Atypical antidepressant, antipsychotic and anxiolytic
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
[Opipramol in behavioral pharmacologic anxiety and depression models].
C Gentsch
Fortschritte der Neurologie-Psychiatrie, 66 Suppl 1, S17-S20 (1999-01-29)
H J Möller et al.
Journal of clinical psychopharmacology, 21(1), 59-65 (2001-02-24)
Opipramol, a drug widely prescribed in Germany, is a tricyclic compound with no reuptake-inhibiting properties. However, it has pronounced D2-, 5-HT2-, and H1-blocking potential and high affinity to sigma receptors (sigma-1 and sigma-2). In early controlled trials, anxiolytic effects were
Hakan Dursun et al.
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 129(7), 861-869 (2009-07-03)
Tricyclic antidepressants are particularly useful in the treatment of endogenous depression. Since the 1950s, tricyclic antidepressants (TCAs) have also been used for the treatment of gastric ulcer disease. Many TCAs have been evaluated for their antiulcer effects, but there are
Update Opipramol
Gahr M, et al.
Fortschritte der Neurologie-Psychiatrie, 139-145 (2017)
[Opipramol in anxiety and somatoform disorders. Results of a controlled study].
H P Volz et al.
Fortschritte der Neurologie-Psychiatrie, 66 Suppl 1, S21-S24 (1999-01-29)
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持
